Exton Michael 4

What Happened Michael Exton, CEO of Lexicon Pharmaceuticals (LXRX), was awarded two derivative equity grants on February 12, 2026: 862,440 and 1,293,670 units, totaling 2,156,110 restricted stock units (RSUs). The awards are reported at $0.00 (no cash paid) and are contingent rights to receive common stock rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-02-12; Report filed: 2026-02-17 (filing is timely; Feb 16, 2026 was a federal holiday).
• Award amounts and price: 862,440 RSUs @ $0.00 and 1,293,670 RSUs @ $0.00 (total 2,156,110 RSUs).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
  • F2: RSUs vest 1/3 of the shares on February 28 of each of the three years following the year of grant.
  • F3: Describes a standard option vesting schedule (25% after 1 year, then monthly over 3 years); this filing’s reported awards are RSUs per F1/F2.
• Transaction type: "A" — Grant/award (derivative), not a market purchase or sale.

Context These are time‑based RSU awards (derivatives) that give the CEO a right to receive shares in the future if vesting conditions are met; they do not involve immediate cash outlay or indicate a direct buy/sell in the open market. For retail investors, awards increase potential insider ownership over time if vested and delivered, but they are routine compensation and should not be interpreted alone as a directional market signal.